NCT06118021CompletedPhase 2
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 17 Oct 2023
- Start date
- 16 Oct 2023
- Primary completion date
- 13 Aug 2024
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT06118021
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 200
- From 16 Oct 2023 to the primary completion date, 13 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Presence of-clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.
- 2\. poor-controlled hypertension. 3. PHQ-9 score≥15. 4. Medical history or illness that affects your weight. 5. Use of any medication or treatment that may have caused significant weight change within 3 months.
- 6\. History of bariatric surgery. 7. History of diabetes. 8. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening.
- 9\. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening.
- 10\. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix.
- 11\. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness.
- 12\. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening.
- 13\. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening.
- 14\. Known or suspected hypersensitivity to trial product(s)or related products. 15. Female who is pregnant,breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method.
- 16\. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme,and their immediate family members.
- 17\. In the judgment of the investigator,there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.
Who the study is looking for
- Male or female subjects,18-65 years of age at the time of signing informed consent.
- BMI≥28.0kg/m2 or 24≤BMI\<28.0 kg/ m2 with at least 1 weight-related comorbidity at screening visit.
- Diet and exercise control for at least 3 months before screening visit,and less than 5 kg self-reported change within the last 3 months.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fourth Affiliated Hospital of Harbin Medical University Coordinator of this site? Confirm its status | Harbin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.